Xiaodong Zhou, Giovanni Targher, Christopher D. Byrne, Virend K. Somers et al.
Background Fatty liver disease in the absence of excessive alcohol consumption is an increasingly common condition with a global prevalence of ~ 25–30% and is also associated with cardiovascular disease (CVD). Since systemic metabolic dysfunction underlies its pathogenesis, the term metabolic (dysfu...
Xufen Zeng, Krista A Varady, Xiangdong Wang, Giovanni Targher et al.
Metabolic dysfunction-associated fatty liver disease (MAFLD) or metabolic dysfunction-associated steatotic liver disease (MASLD), has become the leading cause of chronic liver disease worldwide. Optimal dietary intervention strategies for MAFLD are not standardized. This study aimed to achieve conse...
Gong Feng, Giovanni Targher, Christopher D. Byrne, Yusuf Yılmaz et al.
Background & Aims: This study used the Global Burden of Disease data (2010-2021) to analyze the rates and trends of point prevalence, annual incidence, and years lived with disability (YLDs) for metabolic dysfunction-associated steatotic liver disease (MASLD) in 204 countries. Methods: Total numbers...
Dan‐Qin Sun, Giovanni Targher, Christopher D. Byrne, David C. Wheeler et al.
Background: With the rising global prevalence of fatty liver disease related to metabolic dysfunction, the association of this common liver condition with chronic kidney disease (CKD) has become increasingly evident. In 2020, the more inclusive term metabolic dysfunction-associated fatty liver disea...
Le Zhang, Mortada El‐Shabrawi, Louise A. Baur, Christopher D. Byrne et al.
BACKGROUND Non-alcoholic fatty liver disease (NAFLD) is highly prevalent in children and adolescents, particularly those with obesity. NAFLD is considered a hepatic manifestation of the metabolic syndrome due to its close associations with abdominal obesity, insulin resistance, and atherogenic dysli...
Gong Feng, Yusuf Yılmaz, Luca Valenti, Wai‐Kay Seto et al.
BACKGROUND: This study utilised the Global Burden of Disease data (2010-2021) to analyse the rates and trends in point prevalence, annual incidence and years lived with disability (YLDs) for major chronic liver diseases, such as hepatitis B, hepatitis C, metabolic dysfunction-associated liver diseas...